Document is current
Any future updates will be listed below
-
Authors
M., Pfaeffle
S., Duenkelmann
C, Boesecke
J.K., Rockstroh
C., Schwarze-Zander
-
Funding
Funding for this research was provided by:
Universitätsklinikum Bonn
- License Information
-
More Information
Article History
Received: 26 April 2024
Accepted: 30 October 2024
First Online: 11 November 2024
Declarations
:
: MP has no conflict of interest or personal relationships that could have influenced any aspects of this work. SD has received study grants from AbbVie and ViiV Healthcare. CB has received honoraria for lectures and/or consultancies from AbbVie, Astra Zeneca, Bavarian Nordic, Gilead Sciences, Janssen, MSD, Pfizer, ViiV. CSZ has received study grants and attended advisory boards for AbbVie, ViiV Healthcare, Gilead Sciences, Janssen, and Merck. JKR has received honoraria for participating in advisory boards and speaking at educational events from AbbVie, Gilead Sciences, Janssen,
: This work was performed in accordance with local institutional review board (IRB) guidelines of the University of Bonn (267/22).
: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The institutional review board (IRB) of University Bonn, Germany, approved this study (Nr. 267/22).
